GENETRON HOLDINGS LTD-ADR (GTH)
US37186H2094 - ADR
GTH gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. Both the profitability and financial health of GTH have multiple concerns. GTH is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year GTH has reported negative net income.
GTH had a negative operating cash flow in the past year.
GTH had negative earnings in each of the past 5 years.
GTH had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
GTH has a worse Return On Assets (-82.89%) than 73.64% of its industry peers.
GTH has a worse Return On Equity (-148.03%) than 65.99% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.89% | ||
| ROE | -148.03% | ||
| ROIC | N/A |
ROA(3y)-90.46%
ROA(5y)-106.52%
ROE(3y)-123.51%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 43.25%, GTH is in the better half of the industry, outperforming 79.08% of the companies in the same industry.
GTH's Gross Margin has improved in the last couple of years.
GTH does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.2%
GM growth 5Y10.26%
2. Health
2.1 Basic Checks
GTH does not have a ROIC to compare to the WACC, probably because it is not profitable.
GTH has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, GTH has more shares outstanding
The debt/assets ratio for GTH is higher compared to a year ago.
2.2 Solvency
GTH has an Altman-Z score of -8.92. This is a bad value and indicates that GTH is not financially healthy and even has some risk of bankruptcy.
GTH has a Altman-Z score of -8.92. This is in the lower half of the industry: GTH underperforms 75.68% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that GTH is not too dependend on debt financing.
GTH's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. GTH is outperformed by 61.56% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.92 |
ROIC/WACCN/A
WACC8.31%
2.3 Liquidity
A Current Ratio of 1.82 indicates that GTH should not have too much problems paying its short term obligations.
The Current ratio of GTH (1.82) is worse than 79.59% of its industry peers.
A Quick Ratio of 1.71 indicates that GTH should not have too much problems paying its short term obligations.
GTH has a worse Quick ratio (1.71) than 79.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.71 |
3. Growth
3.1 Past
GTH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -61.92%.
Looking at the last year, GTH shows a very strong growth in Revenue. The Revenue has grown by 22.31%.
Measured over the past years, GTH shows a very strong growth in Revenue. The Revenue has been growing by 45.15% on average per year.
EPS 1Y (TTM)-61.92%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-397.82%
Revenue 1Y (TTM)22.31%
Revenue growth 3Y26.24%
Revenue growth 5Y45.15%
Revenue growth Q2Q342.96%
3.2 Future
GTH is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.08% yearly.
GTH is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 24.46% yearly.
EPS Next Y20.69%
EPS Next 2Y18.08%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year25.16%
Revenue Next 2Y24.46%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
GTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for GTH. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
GTH's earnings are expected to grow with 18.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.08%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for GTH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
GENETRON HOLDINGS LTD-ADR
NASDAQ:GTH (3/28/2024, 8:14:34 PM)
After market: 4.0201 0 (-0.12%)4.025
+0.01 (+0.12%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap127.29M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -82.89% | ||
| ROE | -148.03% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.25% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.67
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.71 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-61.92%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y20.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)22.31%
Revenue growth 3Y26.24%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y